• Journal of the Korean Academy of Child and Adolescent Psychiatry
• /
• 제16권2호
• /
• pp.219-230
• /
• 2005

목적 : 소아, 청소년기 발병 정신분열병은 성인기 발병 정신분열병보다 전구증상을 동반하여 점진적으로 발생하고 심각한 인지기능저하와 신경해부학적 결손을 보여주는 예후가 안좋은 질환으로 알려져왔다. 금번 연구의 목적은 13세를 기준으로 소아, 청소년기 발병 정신분열병을 두 그룹으로 나누어 인구학적 자료, 임상적 특징, 발달학적 지연, 심리학적 특성을 비교하여 소아-청소년기 발병 정신분열병에 대한 이해를 높이고자 하였다. 방법 : 17명의 소아기발병 정신분열병(매우이른 발병) 입원 환아와 16명의 청소년기발병 정신분열병(이른 발병) 입원 환아의 의무기록을 조사하였다. 두 그룹의 기록에서 성별, 연령, 정신과적 과거력, 전구증상 및 기간, 아형, 공존질환, 발달력상 지연, 처방약물 및 용량, 치료반응, 지능지수와 로샤검사를 평가하였다. 결과 : 소아기발병(매우 이른발병)과 청소년기 발병(이른 발병) 정신분열병의 평균 입원 연령은 12.69세$({\pm}2.34)$와 15.13세$({\pm}1.04)$였다. 소아기발병(매우 이른발병)과 청소년기 발병(이른 발병) 정신분열병의 평균 발병 연령은 10.79세 $({\pm}1.95)$와 14.46$({\pm}0.82)$세 였다. 소아기발병 (매우 이른발병)과 청소년기 발병 (이른 발병)의 평균 전구기간은 15.94개월$({\pm}12.33)$과 8.06$({\pm}6.10)$ 개월이었다. 소아기발병 (매우 이른 발병)과 청소년기 발병 (이른 발병)의 관해에까지 이르는데 걸리는 시간은 50.58$({\pm}24.67)$일과 30.06(18.04) 일이었다. 소아기발병 (매우 이른 발병) 그룹에서 관해에까지 이르는 기간이 길수록 일찍 발병 하였다. 두 그룹에서 전체지능, 언어성지능, 동작성 지능은 평균수준이었다. 결론 : 소아기발병(매우 이른 발병)과 청소년기 발병(이른 발병) 정신분열병은 이전의 연구결과와 마찬가지로 전구증상과 함께 전구기간이 존재하고 발달력상 지연이 있을 수 있으며 입원 당시 명백한 정신병적 증상이 존재한다는 점에서는 비슷하지만 청소년기 발병(이른 발병) 그룹에 비해 소아기발병(매우 이른발병) 그룹은 전구기간이 더 짧았으며 발병연령이 늦을수록 관해에 이르는 기간이 짧은 것으로 나타났다.

• Journal of Korean Medical Science
• /
• 제33권52호
• /
• pp.346.1-346.11
• /
• 2018

Background: To evaluate the therapeutic benefits of the treat-to-target (T2T) strategy for Asian patients with early rheumatoid arthritis (RA) in Korea. Methods: In a 1-year, multicenter, open-label strategy trial, 346 patients with early RA were recruited from 20 institutions across Korea and stratified into 2 groups, depending on whether they were recruited by rheumatologists who have adopted the T2T strategy (T2T group) or by rheumatologists who provided usual care (non-T2T group). Data regarding demographics, rheumatoid factor titer, anti-cyclic citrullinated peptide antibody titer, disease activity score of 28 joints (DAS28), and Korean Health Assessment Questionnaire (KHAQ) score were obtained at baseline and after 1 year of treatment. In the T2T group, the prescription for disease-modifying antirheumatic drugs was tailored to the predefined treatment target in each patient, namely remission (DAS28 < 2.6) or low disease activity (LDA) ($2.6{\leq}DAS28$ < 3.2). Results: Data were available for 163 T2T patients and 162 non-T2T patients. At the end of the study period, clinical outcomes were better in the T2T group than in the non-T2T group (LDA or remission, 59.5% vs. 35.8%; P < 0.001; remission, 43.6% vs. 19.8%; P < 0.001). Compared with non-T2T, T2T was also associated with higher rate of good European League Against Rheumatism response (63.0% vs. 39.8%; P < 0.001), improved KHAQ scores (-0.38 vs. -0.13; P = 0.008), and higher frequency of follow-up visits (5.0 vs. 2.0 visits/year; P < 0.001). Conclusion: In Asian patients with early RA, T2T improves disease activity and physical function. Setting a pre-defined treatment target in terms of DAS28 is recommended.

• 한국의학물리학회지:의학물리
• /
• 제26권4호
• /
• pp.229-233
• /
• 2015

정위 방사선치료를 받은 폐암환자에서 결과를 후향적으로 분석하고자 하였다. 연속된 흉부 컴퓨터단층촬영(CT)의 종양의 크기변화 분석을 통해 치료 반응 평가를 조사하였다. 11명의 초기 비소세포폐암환자를 대상으로 정위 방사선치료 선량의 중앙값은 6,000 cGy이고 분할 조사 회수의 중앙값은 5회였다. 경과 관찰기간의 중앙값은 28개월로 치료후 종양의 크기 변화는 총 51회의 CT를 통해 분석하였고, 각 환자당 중앙값 3회의 CT 촬영이 시행되었다. 본 연구에서 치료의 총 반응률은 90.9%로 5명의 환자에서 완전관해와 5명에서 부분관해가 관찰되었다. 부분관해와 완전관해까지의 기간의 중앙 값은 각각 3개월과 5개월이었다. 경과관찰에서 3명의 환자가 병의 진행양상을 나타내었다. 본 연구에서 초기 폐암의 정위방사선치료후 CT 분석을 통해 반응 평가와 함께 치료 반응 시점을 확인할 수 있었다.

• Asian Pacific Journal of Cancer Prevention
• /
• 제15권8호
• /
• pp.3541-3546
• /
• 2014

TEL-AML1 fusion oncogene (t 12; 21) is the most common chromosomal abnormality in childhood acute lymphoblastic leukemia (ALL). This translocation is associated with a good prognosis and rarely shows chemotherapeutic resistance to 3-drug based remission induction phase of treatment as well as overall treatment. Thus, the higher the frequency of this fusion oncogene, the easier to manage childhood ALL in a given region with less intensive chemotherapy. Although global frequency of TEL-AML1 has been reported to be 20-30%, a very low frequency has been found in some geographical regions, including one study from Lahore, Punjab, Pakistan and others from India. The objective of present study was to investigate if this low frequency of TEL-AML1 in pediatric ALL is only in Lahore region or similar situation exists at other representative oncology centers of Pakistan. A total of 167 pediatric ALL patients were recruited from major pediatric oncology centers situated in Lahore, Faisalabad, Peshawar and Islamabad. Patients were tested for TEL-AML1 using nested reverse transcription polymerase chain reaction (RT-PCR). Only 17 out of 167 (10.2%) patients were found to be TEL-AML1 positive. TEL-AML1+ALL patients had favorable prognosis, most of them (82.4%, 14/17) showing early remission and good overall survival. Thus, our findings indicate an overall low frequency of TEL-AML1 in Pakistan pediatric ALL patients, in accordance with lower representation of this prognostically important genetic abnormality in other less developed countries, specifically in south Asia, thus associating it with poor living standards in these ethnic groups. It also indicates ethnic and geographical differences in the distribution of this prognostically important genetic abnormality among childhood ALL patients, which may have a significant bearing on ALL management strategies in different parts of the world.

• Asian Pacific Journal of Cancer Prevention
• /
• 제16권15호
• /
• pp.6663-6668
• /
• 2015

Background: Treatment failure in leukemia is due to either pharmacokinetic resistance or cell resistance to drugs. Materials and Methods: Gene expression of multiple drug resistance protein (MDR-1), multidrug resistance-related protein (MRP) and low resistance protein (LRP) was assessed in 45 pediatric ALL cases and 7 healthy controls by real time PCR. The expression was scored as negative, weak, moderate and strong. Results: The male female ratio of cases was 2.75:1 and the mean age was 5.2 years. Some 26/45 (58%) were in standard risk, 17/45(38%) intermediate and 2/45 (4%) in high risk categorie, 42/45 (93%) being B-ALL and recurrent translocations being noted in 5/45 (11.0%). Rapid early response (RER) at day 14 was seen in 37/45 (82.3%) and slow early response (SER) in 8/45 (17.7%) cases. Positive expression of MDR-1, LRP and MRP was noted in 14/45 (31%), 15/45 (33%) and 27/45 (60%) cases and strong expression in 3/14 (21%), 11/27 (40.7%) and 8/15 (53.3%) cases respectively. Dual or more gene positivity was noted in 17/45 (38%) cases. 46.5 % (7/15) of LRP positive cases at day 14 were in RER as compared to 100% (30/30) of LRP negative cases (p<0.05). All 8 (100%) LRP positive cases in SER had strong LRP expression (p=<0.05). Moreover, only 53.3% of LRP positive cases were in haematological remission at day 30 as compared to 100% of LRP negative cases (p=<0.05). Conclusions: Our study indicated that increased LRP expression at diagnosis in pediatric ALL predicts poor response to early treatment and hence can be used as a prognostic marker. However, larger prospective studies with longer follow up are needed, to understand the clinical relevance of drug resistance proteins.

• 동의생리병리학회지
• /
• 제27권6호
• /
• pp.818-822
• /
• 2013

This report is aimed to investigate the effect of Traditional Korean Therapy (TKT) in treating recurred breast cancer metastasized to lung. A 53-year-old woman who was diagnosed as left breast cancer and underwent surgery, adjuvant chemotherapy and radiotherapy in early 2009 was admitted for the treatment of recurred, metastatic lung cancer in late 2012. She was treated with TKT including acupuncture, moxibustion and pharmacopuncture. The effect was evaluated with positron emission tomogram and computed tomogram (PET-CT). The metastatic tumors in both lungs were disappeared after the treatment for about 2 months. These results suggest that TKT is a therapeutic method to treat metastatic lung cancer originated from breast cancer.

• Journal of Yeungnam Medical Science
• /
• 제36권2호
• /
• pp.85-91
• /
• 2019

The incidence of gastric mucosa-associated lymphoid tissue (MALT) lymphoma is increasing worldwide, but the diagnosis is difficult. Most patients are asymptomatic or complain of nonspecific gastrointestinal symptoms. As the endoscopic features of gastric MALT lymphoma are variable and nonspecific, the possibility of this condition may be overlooked during esophagogastroduodenoscopy, and it remain undiagnosed. Therefore, this condition needs to be considered when an abnormal mucosa is observed during this procedure. Biopsy performed during endoscopy is the primary diagnostic test, but false negative results are possible; large numbers of samples should be collected from both normal and abnormal mucosae. Endoscopic ultrasonography is useful to assess the depth of invasion and to predict the treatment response. After treatment, follow-up tests are required every 3 months until complete remission is achieved, and annually thereafter. Early diagnosis of gastric MALT lymphoma is difficult, and its diagnosis and follow-up require wide experience and competent endoscopic technique.

• Journal of Digestive Cancer Research
• /
• 제10권2호
• /
• pp.74-81
• /
• 2022

Colorectal peritoneal metastasis has been an incurable disease for centuries. However, since the new millennium, recent advancements in therapies are achieved with modern chemotherapeutic agents, target agents, and immune checkpoint blockade introduction. Modern chemotherapies, from a nearly nonexistent median survival if untreated, have raised the duration to 16 months with target agents. Experts have once again surpassed its limit by introducing intraperitoneal chemotherapy and cytoreductive surgery (CRS). Numerous clinical trials regarding CRS and hyperthermic intraperitoneal chemotherapy have now opened new doors in peritoneal carcinomatosis treatment, even securing complete remission. In addition, up-to-date modalities, such as pressurized intraperitoneal aerosol chemotherapy and immunotherapies, showed promising results at an early stage.

• Asian Pacific Journal of Cancer Prevention
• /
• 제15권24호
• /
• pp.10967-10970
• /
• 2015

Objective: To analyze the efficacy and survival associated factors of gefitinib combined with cisplatin and gemcitabine for advanced non-small cell lung cancer. Materials and Methods: A total of 57 patients with advanced non-small cell lung cancer (NSCLC), who received platinum-based chemotherapy regimens for more than 1 cycle, were treated with gefitinib combined with cisplatin and gemcitabine until disease progression. Efficacy, survival time and adverse reactions were observed. The Kaplan-Meier method was adopted for analysis of survival and Cox regression for associated influencing factors. Results: The patients were followed up until October 31, 2013, and the median follow-up time was 19 months. Of 57 patients, there were 4 (7.0%) with complete remission (CR), 8 (14.0%) with partial remission, 31 (54.4%) with stable disease, and 14 (24.6%) with disease progression. The remission rate was 21.1% and the disease control rate was 75.4%. The median progression-free survival (PFS) time and the median overall survival time were 10 months and 15.2 months. The one-year, two-year and three-year survival rates were 47.4%, 23.3% and 10.0%. Gender and pathological types were the independent risk factors influencing PFS time (P=0.028, P=0.009). Tumor pathological type and early efficacy were independent factors for the prognosis (P=0.018, P=0.000). Adverse reactions were mostly rashes of I~II degree and diarrhea and slightly increasing level of aminopherase. The skin adverse event incidence of III degree or above was 1.8% (1/57) and brain metastasis was foudn in 31.6% (18/57). Conclusions: Gefitinib combined with cisplatin andgemcitabine, is effective for patients with IIIb~IV NSCLC who received multiple cycles of chemotherapy.

• Tuberculosis and Respiratory Diseases
• /
• 제71권4호
• /
• pp.266-270
• /
• 2011

Background: Photodynamic therapy (PDT) is effective in managing small superficial early lung cancer patients who were deemed nonsurgical candidates. However, we do not have any previous report on the usefulness of PDT in early lung cancer in South Korea. Thus we report here our experience of PDT in early lung cancer patients. Methods: 10 patients who underwent PDT for managing early lung cancer between June 2006 and July 2010 were analyzed. PDT was carried out 48 hours after photosensitizer injection. Re-bronchoscopy was carried out 48 hours after PDT in order to remove a necrotic tissue from the PDT site. For evaluation of PDT response, bronchoscopy and chest computed tomography (CT) were performed after 3 months. Results: The median age of patients was 69 (49~77) and all patients were male. The smoking history of patients was 48 (20~75) pack-year and the median follow up of patients was 25 (11~52) months. Complete remission was observed in 10 patients and the recurrence of lung cancer was observed in 3 patients. Out of 10 patients, 3 patients died (one case of lung cancer progression and two cases of pneumonia). Conclusion: The PDT is a safe and effective treatment in early lung cancer patients who are not suitable for surgical resection. The PDT in clinical practice is an attractive option in the treatment of early lung cancer.